newsfilter
← Latest News
Business Wire·

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference

Epetraborole's potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (NASDAQ:ANTX), a